What does this research mean for the field?

Prior daratumumab exposure during induction therapy does not adversely affect CD34⁺ stem cell mobilization, collection yield, engraftment, or early post-transplant complications in patients undergoing autologous hematopoietic stem cell transplantation. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To assess whether prior induction therapy with daratumumab impairs CD34+ stem cell mobilization, collection yield, engraftment kinetics, or early post-transplant complications in patients undergoing autologous hematopoietic stem cell transplantation.

September 8, 2026Hematology Transfusion and Cell TherapyOpen Access

Real-world outcomes of CD34⁺ mobilization and early autologous hematopoietic stem cell transplantation recovery after daratumumab-based induction

View Full Paper

Ask AI

Bookmark

Authors

AAArthur Sousa dos AnjosUniversidade Federal do Rio de Janeiro CMClaudio Verti MendonçaUniversidade Federal do Rio de Janeiro SMSimone MaradeiInstituto Nacional do Câncer

Discussion

Member takes

Implication

Retrospective cohort study reveals comparable stem cell collection and engraftment after daratumumab induction in multiple myeloma, indicating autologous transplant feasibility.

Key Points

To assess whether prior induction therapy with daratumumab impairs CD34+ stem cell mobilization, collection yield, engraftment kinetics, or early post-transplant complications in patients undergoing autologous hematopoietic stem cell transplantation.
Retrospective, single-center cohort study of 100 adult patients with multiple myeloma who underwent autologous hematopoietic stem cell transplantation.
Extracted medical record data on CD34+ counts, mobilization regimens, plerixafor utilization, collection yields, engraftment timing, and early post-transplant adverse events, comparing patients with and without prior daratumumab exposure.
Mobilization success was high across both arms with zero mobilization failures; peripheral CD34+ counts during mobilization were 15 cells/µL in the daratumumab group versus 19 cells/µL in controls (p = 0.220), and plerixafor utilization was 26% versus 24% (p = 1.0).
Final CD34+ collection yields were 3.80 × 10⁶ cells/kg in daratumumab-treated patients compared to 4.07 × 10⁶ cells/kg in controls (p = 0.358), with a median time to neutrophil engraftment of 10 versus 10.5 days (p = 0.539).
Early post-transplant complication rates showed no significant differences, including overall rates of engraftment syndrome (25%), febrile neutropenia (89%), bacteremia (23%), and intensive care unit admission (12%), with one death occurring in the control cohort.

Cite This Study

Anjos et al. (2026) studied this question.

synapsesocial.com/papers/6a9fd72a58e84d0ff5b45ad7 https://doi.org/10.1016/j.htct.2026.106531

View Full Paper

Ask AI

Bookmark

Implication

Retrospective cohort study reveals comparable stem cell collection and engraftment after daratumumab induction in multiple myeloma, indicating autologous transplant feasibility.

Real-world outcomes of CD34⁺ mobilization and early autologous hematopoietic stem cell transplantation recovery after daratumumab-based induction

Discussion

Member takes

Implication

Key Points

Cite This Study

Real-world outcomes of CD34⁺ mobilization and early autologous hematopoietic stem cell transplantation recovery after daratumumab-based induction

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider